Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development and Validation of Nomogram-Based Predictive Models for Severe Hypoglycemia in Adults With Type 1 Diabetes Treated With Multiple Daily Injections: The SEHYPAN Study.

Diabetes/metabolism research and reviews·2026

Same author

[Evaluation of improved nutritional status in patients over 60 years with 6-month follow-up by a nutritionist in a hospital setting in Almería. The MOR-NUT study].

Nutricion hospitalaria·2023

Same author

Application of the changes in the Standards of Medical Care in Diabetes ADA 2021 to clinical practice in our country. SED-SEEN document.

Endocrinologia, diabetes y nutricion·2021

Same author

Application of the changes in the Standards of Medical Care in Diabetes ADA 2021 to clinical practice in our country. SED-SEEN document.

Endocrinologia, diabetes y nutricion·2021

Same author

Trends on Diabetes Mellitus's healthcare management in Spain 2007-2015.

Diabetes research and clinical practice·2019

Same author

Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: Expert recommendations using a Delphi approach.

European journal of ophthalmology·2019

Search research articles

Related Experiment Video

Updated: May 7, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution

Published on: April 16, 2019

Is treatment with liraglutide efficient?

Pedro Mezquita Raya¹, Rebeca Reyes García²

¹Unidad de Endocrinología, Nutrición y Riesgo Vascular, Complejo Hospitalario Torrecárdenas, Almería, España; Servicio de Endocrinología, Clínica San Pedro, Almería, España.

Endocrinologia Y Nutricion : Organo De La Sociedad Espanola De Endocrinologia Y Nutricion

|September 28, 2013

Summary

Liraglutide, a GLP-1 receptor agonist for type 2 diabetes, improves cardiovascular risk factors and body weight. Despite higher costs, it proves cost-effective in managing type 2 diabetes mellitus (T2DM).

Keywords:

Cost-effectiveness Coste-efectividad Diabetes mellitus tipo 2 Liraglutida Liraglutide National Institute for Health and Clinical Excellence Type 2 diabetes mellitus

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Related Experiment Videos

Last Updated: May 7, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution

Published on: April 16, 2019

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Area of Science:

Pharmacoeconomics
Cardiology
Endocrinology

Background:

Drug treatment efficiency is crucial given limited health resources.
Liraglutide is a GLP-1 receptor agonist for type 2 diabetes mellitus (T2DM).
Liraglutide offers benefits beyond glycemic control, including weight and cardiovascular risk factor improvement.

Purpose of the Study:

To review evidence on liraglutide's effects on cardiovascular risk factors.
To assess how these improvements impact liraglutide's cost-effectiveness.
To analyze the overall cost-effectiveness of liraglutide in T2DM management.

Main Methods:

Narrative review of existing studies.
Analysis of clinical effects of liraglutide.
Evaluation of direct costs associated with T2DM management.
Assessment of cardiovascular risk factors and body weight changes.

Main Results:

Liraglutide significantly improves body weight and cardiovascular risk factors in T2DM patients.
Evidence supports liraglutide's positive impact on multiple cardiovascular risk indicators.
The drug demonstrates effectiveness in managing T2DM beyond glycemic control.

Conclusions:

Liraglutide is a cost-effective treatment option for type 2 diabetes mellitus.
Improved cardiovascular risk factors contribute to liraglutide's favorable cost-effectiveness profile.
Despite a higher initial cost, liraglutide offers long-term economic benefits in T2DM care.